EMEA-002863-PIP01-20
Submitted by Anonymous (not verified) on 24 October 2024 - 14:22
EMEA-002863-PIP01-20
EMEA-001043-PIP01-10-M03
Submitted by Anonymous (not verified) on 24 October 2024 - 14:20
EMEA-001043-PIP01-10-M03
EVVet3 EVWeb Production - Release notes
Submitted by Anonymous (not verified) on 24 October 2024 - 14:15
EVVet3 EVWeb Production - Release notes
Fourth veterinary big data stakeholder forum, Online, European Medicines Agency, Amsterdam, the Netherlands, from 14 October 2024, 10:00 (CEST) to 14 October 2024, 15:00 (CEST)
Submitted by Anonymous (not verified) on 24 October 2024 - 14:13
Fourth veterinary big data stakeholder forum, Online, European Medicines Agency, Amsterdam, the Netherlands, from 14 October 2024, 10:00 (CEST) to 14 October 2024, 15:00 (CEST)
Human medicines European public assessment report (EPAR): Onbevzi, bevacizumab, Date of authorisation: 11/01/2021, Revision: 5, Status: Withdrawn (authorisation)
Submitted by Anonymous (not verified) on 24 October 2024 - 13:48
Human medicines European public assessment report (EPAR): Onbevzi, bevacizumab, Date of authorisation: 11/01/2021, Revision: 5, Status: Withdrawn (authorisation)
Pharmacovigilance Risk Assessment Committee (PRAC): 24 - 27 November 2025, European Medicines Agency, Amsterdam, the Netherlands, from 24 November 2025 to 27 November 2025
Submitted by Anonymous (not verified) on 24 October 2024 - 12:20
Pharmacovigilance Risk Assessment Committee (PRAC): 24 - 27 November 2025, European Medicines Agency, Amsterdam, the Netherlands, from 24 November 2025 to 27 November 2025
Pharmacovigilance Risk Assessment Committee (PRAC): 27 - 30 October 2025, European Medicines Agency, Amsterdam, the Netherlands, from 27 October 2025 to 30 October 2025
Submitted by Anonymous (not verified) on 24 October 2024 - 12:19
Pharmacovigilance Risk Assessment Committee (PRAC): 27 - 30 October 2025, European Medicines Agency, Amsterdam, the Netherlands, from 27 October 2025 to 30 October 2025
Pharmacovigilance Risk Assessment Committee (PRAC): 29 September - 2 October 2025, European Medicines Agency, Amsterdam, the Netherlands, from 29 September 2025 to 2 October 2025
Submitted by Anonymous (not verified) on 24 October 2024 - 12:18
Pharmacovigilance Risk Assessment Committee (PRAC): 29 September - 2 October 2025, European Medicines Agency, Amsterdam, the Netherlands, from 29 September 2025 to 2 October 2025
Pharmacovigilance Risk Assessment Committee (PRAC): 1 - 4 September 2025, European Medicines Agency, Amsterdam, the Netherlands, from 1 September 2025 to 4 September 2025
Submitted by Anonymous (not verified) on 24 October 2024 - 12:17
Pharmacovigilance Risk Assessment Committee (PRAC): 1 - 4 September 2025, European Medicines Agency, Amsterdam, the Netherlands, from 1 September 2025 to 4 September 2025
Pharmacovigilance Risk Assessment Committee (PRAC): 4 - 7 August 2025, European Medicines Agency, Amsterdam, the Netherlands, from 4 August 2025 to 7 August 2025
Submitted by Anonymous (not verified) on 24 October 2024 - 12:16
Pharmacovigilance Risk Assessment Committee (PRAC): 4 - 7 August 2025, European Medicines Agency, Amsterdam, the Netherlands, from 4 August 2025 to 7 August 2025